• Genetic Tests Identify Risk of Irinotecan-Induced Toxicity: John Logan Black, M.D.

  • Nov 12 2024
  • Length: 16 mins
  • Podcast

Genetic Tests Identify Risk of Irinotecan-Induced Toxicity: John Logan Black, M.D.

Listen for free

View show details

  • Summary

  • John Logan Black, M.D., explains how Mayo Clinic Laboratories' UGT1A1 tests (Mayo IDs: U1A1Q and UGTFZ) identify genetic variants that increase the risk of potentially life-threatening reactions to irinotecan, a chemotherapy agent.

    Speaker 3: (00:32)
    Could you give us a brief overview about your background and yourself?

    Speaker 3: (02:16)
    Could you explain the role of the UGT1A1 gene and its significance in the pharmacogenomics of irinotecan?

    Speaker 3: (05:34)
    What specific tests do we offer for UGT1A1 at Mayo Clinic Laboratories?

    Speaker 3: (08:01)
    Can you clarify the difference between targeted genotyping and full gene sequencing, and when each method is most appropriate?

    Speaker 3: (10:36)

    Could you elaborate on the specific clinical indications for testing in relation to irinotecan?

    Speaker 3: (13:27)
    How do UGT1A1 test results impact the dosing of irinotecan? What should clinicians consider when using those results?

    Speaker 3: (14:02)
    Are there any other factors or related genes that should be considered alongside UGT1A1, particularly for cancer therapy?
    Show more Show less
Show more Show less
activate_Holiday_promo_in_buybox_DT_T2

What listeners say about Genetic Tests Identify Risk of Irinotecan-Induced Toxicity: John Logan Black, M.D.

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.com reviews

Amazon reviews
No Reviews are Available